441
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
Condition(s):Multiple MyelomaLast Updated:February 9, 2022Active, not recruiting
Refractory Multiple Myeloma: 1467 Clinical Trials, Page 45 of 147
Hide Studies Not Open or Pending
442
SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma
Condition(s):Refractory Multiple MyelomaLast Updated:February 4, 2021Recruiting
443
Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)
Condition(s):Multiple MyelomaLast Updated:May 27, 2022Active, not recruiting
444
Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma
Condition(s):Multiple MyelomaLast Updated:April 23, 2009Withdrawn
445
Cevostamab Following CAR T Cell Therapy for RRMM
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:April 10, 2023Not yet recruiting
446
Ixazomib Citrate, Pomalidomide, Dexamethasone, and Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Recurrent Plasma Cell Myeloma; Refractory Plasma Cell MyelomaLast Updated:July 21, 2022Active, not recruiting
447
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:May 23, 2023Recruiting
448
Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
Condition(s):Multiple MyelomaLast Updated:March 28, 2023Recruiting
449
Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma
Condition(s):MyelomaLast Updated:November 15, 2019Terminated
450
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:February 10, 2023Active, not recruiting